QTc prolongation in patients with hearing loss: Electrocardiographic and genetic study

Agnieszka Sanecka1, Elżbieta Katarzyna Biernacka2, Małgorzata Szperl3, Magdalena Sosna4, Małgorzata Mueller-Malesińska5, Urszula Koźicka6, Rafal Baranowski2, Agnieszka Kosiec7, Hubert Łazarczyk8, Henryk Skarżyński4, Piotr Hoffman9, Katarzyna Bieganowska7, Ryszard Piotrowicz1

1Department and Clinic of Cardiac Rehabilitation and Noninvasive Electrocardiology, Institute of Cardiology, Warsaw, Poland
2Department of Congenital Cardiac Defects, Institute of Cardiology, Warsaw, Poland
3Molecular Biology Laboratory, Institute of Cardiology, Warsaw, Poland
4Institute of Physiology and Pathology of Hearing, World Hearing Center, Nadarzyn, Poland
5Department of Arrhythmia, Institute of Cardiology, Warsaw, Poland
6Institute of Cardiology, Warsaw, Poland
7Department of Cardiology, Children’s Memorial Health Institute, Warsaw, Poland

Abstract

Background: The aim of the study was to determine, whether electrocardiogram (ECG) screening could reduce the risk of sudden cardiac death in patients with hearing loss through the early diagnosis of Jervell and Lange-Nielsen syndrome and the introduction of the therapy.

Methods: One thousand and eighty patients with hearing loss (aged 21.8 ± 19.9 years) underwent ECG. Additionally, all subjects were asked to complete a 3-question survey. Those who met, at least, one of the high-risk criteria underwent further cardiac assessment and genetic testing.

Results: QTc assessment was possible in 1,027 patients. Mean QTc measured 422.8 ± 23.7 ms in 313 women, 414.9 ± 27.7 ms in 273 men and 421.1 ± 21.5 ms in 441 children (individuals younger than 14 years). Abnormal QTc was found in 13 (4.1%) women, 20 (7.3%) men, and 72 (16.3%) children. In the studied group, no recessive mutation of KNCQ1 or KCNE1 was found. In 6 patients, other mutations were found: in KNCQ1 (n = 1), in KCNH2 (n = 3) and in SCN5A (n = 1), which were pathogenic for long-QT-syndromes (LQTS), and 2 mutations of unknown clinical significance in SCN5A. Overall, out of these 6 patients LQTS was diagnosed in 3 asymptomatic patients, but with abnormal QTc and in 2 patients with normal QTc, but who were previously treated for epilepsy.

Conclusions: Jervell and Lange-Nielsen syndrome is a very rare condition even in a population with hearing loss. In this population, the prevalence of prolonged QT interval is increased over the general population. Further investigations are necessary. (Cardiol J 2016; 23, 1: 34–41)

Key words: long-QT syndrome, hearing loss, Jervell and Lange-Nielsen syndrome, electrocardiogram
Introduction

The Jervell Lange-Nielsen syndrome (JL-N) (a long-QT-syndrome variant associated with the deafness) is a rare and severe type of long-QT-syndrome (LQTS). It is an inherited autosomal recessive disorder. The disease is caused by the mutations in at least one of the two genes: KCNQ1 or KCNE1. These genes encode alpha and beta subunits of the potassium channel which mediates I\textsubscript{Ks} current \[1\] and their mutations result in an abnormal function of the potassium channel and subsequent prolongation of the ventricular repolarization phase. The latter predisposes to ventricular tachyarrhythmias such as ‘torsade de pointes’ or ventricular fibrillation and can lead to fainting, syncope or sudden cardiac death.

The JL-N syndrome is characterized by high mortality in young age (27% of sudden deaths occur by the age of 8.5 years). Sudden cardiac death is often the first manifestation of the heart being involved in the disease process \[1\]. Electrocardiography (ECG) changes, like an extremely abnormal repolarization pattern and a very long QTc interval (557 ± 65 ms), typically occur very early in life \[1\]. The presence of such changes in a person with the hearing loss immediately raises a suspicion of a JL-N syndrome and allows implementation of prophylactic life-saving treatment. Besides the British Association of Paediatricians in Audiology (BAPA) and British Association of Audiological Physicians (BAAP) to screen every patient with congenital hearing loss with ECG, other organizations do not recommend routine ECG in this group of patients \[2\]. However, guidelines clearly do emphasize ECG utility in patients with a history of loss of consciousness, arrhythmia or family history of sudden death \[3\].

The aim of this study was to determine whether ECG screening could reduce the risk of sudden cardiac death in patients with hearing loss through an early diagnosis of JL-N syndrome and introduction of the therapy. ECG studies were performed in patients with hearing loss to identify subjects with long QTc interval (LQT). Subsequently, LQT (including JL-N) syndromes were confirmed by cardiac and genetic testing. Theoretically, an early identification of JL-N syndrome would allow an introduction of appropriate treatment and prevention of serious arrhythmias or sudden cardiac death.

Methods

Studied population

In the prospective manner, 1,080 patients were enrolled from two outpatient audiology clinics and three schools for children with hearing loss. Studied population consisted of 562 (52%) females and 518 (48%) males with confirmed hearing loss, aged 21.8 ± 19.9 years (0.16–84 years). It also included 454 (42%) children aged less than 14 years. All underwent a 12-lead ECG.

For the purpose of the study, we used the following criteria for hearing loss: sensorineural hearing loss of 30 dB HL or more (calculated as average hearing thresholds for frequencies relevant to speech understanding 500 Hz, 1000 Hz, 2000 Hz and 4000 Hz). Of all studied, 301 patients had cochlear implants. 707 patients were divided into six groups according to the type and the degree of hearing loss per audiological data. These were only available in patients from outpatient clinics — we had no access to the precise audiological data of children examined at schools. The majority of patients (n = 525) had congenital sensorineural bilateral hearing loss and were divided into four groups: 1) patients with bilateral significant or profound sensorineural hearing loss (defined as the average hearing threshold of 70 dB HL or more at frequencies: 500 Hz, 1000 Hz, 2000 Hz and 4000 Hz, and not meeting criteria for the forth group) (n = 426), 2) medium-grade sensorineural hearing loss (defined as the average hearing threshold between 69 dB HL and 50 dB HL at frequencies: 500 Hz, 1000 Hz, 2000 Hz, and 4000 Hz, and not meeting criteria for the forth group) (n = 454), 3) low-grade sensorineural hearing loss (defined as the average hearing threshold between 49 dB HL and 30 dB HL at frequencies: 500 Hz, 1000 Hz, 2000 Hz, 4000 Hz, and not meeting criteria for the fourth group) (n = 55), 4) bilateral partial deafness (patients with low-frequency residual hearing, defined as the average hearing threshold of 60 dB HL at frequencies: 125 Hz, 250 Hz, and 500 Hz) (n = 27). Additionally, there were 182 patients with hearing loss of unknown cause: group 5) patients with a history of an episode of idiopathic sudden deafness (n = 19), 6) with acquired varying degrees of bilateral sensorineural hearing loss of unknown etiology (n = 163).

Electrocardiographic testing

All 1,080 patients underwent a 12-lead ECG. ECG recordings (recorded with a sampling frequency of 1000 Hz) were performed in the outpatient Audiology Departments and schools and sent for the evaluation to the cardiology center using the Cardiology Information Management System Sentinel Reynolds Medical. ECG evaluation was done by a single observer (cardiologist). QT interval
measurements were performed electronically on the 5× enlarged views of evolutions with an accuracy of 1 ms. The QT interval was measured in the same cardiac cycle in at least three leads (usually in leads: II, V2, and V5). To correct the QT interval for heart rates between 50 and 120 bpm Bazett’s formula was used. For faster and slower heart rates Hodges formula was used. Heart rate was calculated based on the RR interval measurement. We selected the RR interval preceding the QRS complex — the one for which QT interval was being measured. Patients with QRS complexes of 120 ms or more were excluded from the average QTc calculation. Fifty-three recordings were excluded from the calculation of the mean QTc due to the presence of any of the following: pre-excitation pattern, intraventricular conduction block, QRS complexes measuring 120 ms or more, ventricular pacing or artifacts, as all these could prevent reliable QTc determination. Based on differences in physiology of cardiac conduction and inherent varying reference values for QTc between children and adults, males and females, study population was divided into 3 categories: 1) 454 (42%) children younger than 14 years (232 were girls), 2) 330 (30.5%) females 14 or more years old and 3) 296 (27.5%) males 14 or more years old [4]. All subjects were asked to complete a 3-question survey on the presence of 1) personal history of loss of consciousness or fainting associated with palpitations, 2) personal history of epilepsy, 3) family history of the sudden death or loss of consciousness. Based on the number of positive answers, and calculated QTc length some subjects were rated as “high-risk”. Specific criteria for such rating were: 1) positive response to all 3 questions in the survey, 2) any 2 positive responses and QTc longer than 440 ms, 3) QTc longer than 455 ms. Patients rated as “high-risk” attended further cardiac evaluation including ECG exercise testing, 24-h Holter-ECG, and genetic testing. During exercise testing the occurrence of ventricular arrhythmias and QTc length (before exercise, at peak exercise and after exercise test) were evaluated. Holter results were assessed for the presence of ventricular arrhythmias. Automatic measurement and calculation of the QT and QTc intervals was performed wherever possible.

Genotyping

DNA was isolated from peripheral blood leukocytes using the phenol method. Four genes were sequenced: KCNQ1, KCNH2, SCN5A, and KCNE1. We used the Next-Generation Sequencing and traditional Sanger method. Analysis was performed on the Amplicon Variant Analysis software. Primers used in genotyping were designed in the Laboratory of Molecular Biology of the Institute of Cardiology and they are available upon request. The presence of the pathogenic mutations was confirmed with Sanger method.

Consenting and approval

The Bioethics Committee of the Institute of Cardiology approved the project. All enrolled patients (or when applicable their legal guardians) have given their written informed consent to participate. Written informed consent has been additionally received from patients rated as high-risk who agreed to participate in further steps of the study.

Results

Characteristics of the study population

Electrocardiogram was analyzed in 1,080 patients (53 recordings were excluded from the calculation of the mean QTc due to the presence of any of the following: pre-excitation pattern, intraventricular conduction block, QRS complexes measuring 120 ms or more, ventricular pacing or artifacts). The survey was completed by 887 (82%) patients; 107 out of 887 subjects reported a loss of consciousness or palpitations associated with fainting, 40 subjects were diagnosed with epilepsy and 46 people had a family history of sudden death or loss of consciousness. Altogether 96 (8.9%) patients met criteria for the high risk: 6 patients met the 1st criterion, 3 patients met the 2nd criterion, and 88 patients met the 3rd criterion.

Electrocardiogram

The results of the QTc calculations, with an accuracy of 1 ms, are demonstrated in Table 1. In females 14 years old and older mean QTc was 422.8 ± 23.7 ms, ranging from 352 ms to 495 ms. Out of these females, 13 (4.1%) had QTc exceeding the reference value. Their mean QTc was 472.2 ± 10.1 ms. In males 14 years old and older, mean QTc was 414.9 ± 27.7 ms, ranging from 343 ms to 517 ms. Out of these males, 20 (7.3%) had prolonged QTc with a mean value of 467.8 ± 16.4 ms and 1 male had QTc longer than 500 ms. Mean QTc interval in children (individuals younger than 14 years old) was 421.1 ± 21.5 ms, ranging from 366 ms to 483 ms. QTc exceeding 440 ms was observed in 72 (16.3%) children. However, the QTc prolongation did not exceed 500 ms. Therefore, nobody was diagnosed with LQTS meeting solely a “QTc
length” criterion. In the entire study population, no statistically significant correlation between hearing loss pattern and the presence of QTc prolongation was found (p = 0.0596). From the 96 patients who fulfilled the criteria of the high-risk group, 62 attended follow-up appointments. The automatic calculation of the QT and QTc intervals throughout the 24 h period was performed in 35 subjects with Holter monitoring. In 7 patients, periodic QTc prolongation of up to 643 ms was found. It was present in less than 1% of monitoring time. Two other patients had an abnormal QTc response to exercise. However, none of these patients had syncope or arrhythmia. Before genotyping was completed, LQTS diagnosis was made in 3 asymptomatic patients based on the history, another ECG, exercise testing and Holter monitoring (HRS/EHRA/APHRS Expert Consensus 2013 criteria were used) (Table 2) [5].

Other ECG abnormalities

We analyzed the incidence of other ECG abnormalities in the study population. We found atrial rhythm in 15 patients, wandering atrial pacemaker in 2 patients, sinus bradycardia in 125 patients, atrial fibrillation in 3 patients, first-degree atrioventricular block in 19 patients, signs of pre-excitation in 2 patients, right bundle branch block (complete or incomplete) in 39 patients, left anterior fascicular block in 12 patients,complete left bundle branch block in 2 patients, nonspecific intraventricular conduction disturbances in 35 patients, signs of left atrial hypertrophy in 24 patients, signs of myocardial ischemia in 5 patients, and signs of myocardial necrosis in 4 patients.

### Table 1. The results of QTc measurements by enlarged evolution method with an accuracy of 1 ms.

<table>
<thead>
<tr>
<th></th>
<th>Minimal QTc [ms]</th>
<th>Maximal QTc [ms]</th>
<th>Mean QTc ± SD [ms]</th>
<th>Number of subjects with QTc above the normal range (% of the group)*</th>
<th>Mean QTc ± SD in subjects with QTc above the normal range [ms]*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female ≥ 14 years of age (n = 313)</td>
<td>352</td>
<td>495</td>
<td>422.8 ± 23.7</td>
<td>13 (4.1%)</td>
<td>472.2 ± 10.1</td>
</tr>
<tr>
<td>Male ≥ 14 years of age (n = 273)</td>
<td>343</td>
<td>517**</td>
<td>414.9 ± 27.7</td>
<td>20 (7.3%)</td>
<td>467.8 ± 16.4</td>
</tr>
<tr>
<td>Children &lt; 14 years of age (n = 441)</td>
<td>366</td>
<td>483</td>
<td>421.1 ± 21.5</td>
<td>72 (16.3%)</td>
<td>454.0 ± 11.8</td>
</tr>
</tbody>
</table>

*Normal QTc range: ≤ 460 ms in women, ≤ 450 ms in men, ≤ 440 ms in children under 14 years of age; **QTc > 500 ms was found in one male; SD — standard deviation

### Table 2. The results of QTc in other cardiac investigations in high-risk patients that attended their appointment.

<table>
<thead>
<tr>
<th></th>
<th>QT ± SD [ms]</th>
<th>QTc ± SD [ms]</th>
</tr>
</thead>
<tbody>
<tr>
<td>ECG (n = 50)</td>
<td>388.76 ± 31.48</td>
<td>411.86 ± 24.02</td>
</tr>
<tr>
<td>ECG exercise test (n = 40):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rest</td>
<td>364 ± 32.27</td>
<td>412 ± 31.56</td>
</tr>
<tr>
<td>Peak exercise</td>
<td>255 ± 32.52</td>
<td></td>
</tr>
<tr>
<td>Recovery</td>
<td>346 ± 34.33</td>
<td>441 ± 35.05</td>
</tr>
<tr>
<td>Holter ECG (n = 35):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>380.94 ± 30.7</td>
<td>432.77 ± 21.35</td>
</tr>
<tr>
<td>Maximal</td>
<td>435.68 ± 35.49</td>
<td>509.55 ± 35.47</td>
</tr>
</tbody>
</table>

Percentage of patients with certain QTc values:
- > 440 ms 4.08%
- > 460 ms 3.80%
- > 470 ms 2.45%
- > 480 ms 2.34%
- > 500 ms 0.97%

ECG — electrocardiogram; SD — standard deviation
Sixty blood samples for genetic testing were obtained. We have not found recessive mutations of 
*KNCQ1* or *KCNE1* typical for JL-N in any of the studied subjects. However, in 6 (10% of all geno-
typed) patients we have found other pathogenic mu-
tations in the *KCNQ1* (1), *KCNH2* (3), and *SCN5A* (1) 
genes and two mutations of unknown clinical 
significance, both in the *SCN5A* gene (Table 3). 
Three of these 6 patients had the R1047L muta-
tion in the *KCNH2* gene, which is associated with 
the LQTS type 2 (LQT2). One of those 6 patients 
had coexistent R1047L mutation in the *KCNH2* gene 
with the R53Q mutation of unknown clinical 
significance in the *SCN5A* gene, which had been 
previously reported only once. Separately, 3 of 
those 6 patients were earlier diagnosed with epi-
lepsy. Finally, in 2 subjects of those 3 patients we 
have made the diagnosis of LQT2. These patients 
had been earlier incorrectly diagnosed with epilepsy 
and were unsuccessfully treated with antiepileptic 
drugs. Both of these patients fulfilled first high-
risk criterion: they both had a history of loss of 
consciousness, previous diagnosis of epilepsy and 
a positive family history, and they had no significant 
QT prolongation: 396 ms and 352 ms, respectively. 
In other 3 patients, LQTS type 1, 2 and 3 have been 
diagnosed, respectively. Out of other 2 of those 
6 patients, 1 was found to have a P2005A mutation 
in the *SCN5A* gene, and another 1 had a R1047L 
mutation in the *KCNH2* gene. They did not present 
any other symptoms of LQTS, despite significant 
QTc prolongation. In the last one of those 6 pa-
tients, who previously had been diagnosed with 
epilepsy and alpha-mannosidosis and who had 
QTc of 435 ms, a Q1033R mutation in exon 17 of 
the *SCN5A* gene was detected. This mutation has 
unknown clinical significance. The patient has not 
been diagnosed with LQTS.

### Polymorphisms

Thirteen polymorphisms were identified in the study group (Table 4) including: 2 polymor-
phisms in the *KCNQ1* gene (exons 13 and 16), 
6 polymorphisms in the *KCNH2* gene (exons 6, 7, 
8, 11 and 12), 4 polymorphisms in the *SCN5A* gene 
(exons 2, 12, 17 and 28) and 1 polymorphism in 
the *KCNE1* gene in exon 3. These allele frequen-
cies were similar in the hearing loss population 
and the general population. Twelve patients had 
a K897T polymorphism in the *KCNH2* gene as-
sociated with the dysfunction of the potassium 
channel mediating IKr current. The Wilcoxon 
test was used to compare the QTc duration of the 
individuals with the found polymorphisms to the 
QTc duration of those without the polymorphisms. 
Only one (Y666Y) of the polymorphisms was as-
sociated with prolonged QTc reaching statistical 
significance (p = 0.008). Due to the small number 
(n = 7) of individuals carrying this polymorphism, 
these results have to be interpreted carefully and 
require further confirmation.

### Table 3. Mutations found in high-risk patients with hearing loss.

<table>
<thead>
<tr>
<th>Gender, age [years]</th>
<th>High-risk criteria fulfilled</th>
<th>QTc [ms]</th>
<th>Gene, exon</th>
<th>Amino acid changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, 15</td>
<td>Asymptomatic</td>
<td>480</td>
<td>KCNQ1 exon 13</td>
<td>R555H, pathogenic</td>
</tr>
<tr>
<td>Female, 13</td>
<td>Syncope</td>
<td>396</td>
<td>KCNH2 exon 13</td>
<td>R1047L, pathogenic</td>
</tr>
<tr>
<td>Male, 19</td>
<td>Syncope</td>
<td>352</td>
<td>KCNH2 exon 13</td>
<td>R1047L, pathogenic</td>
</tr>
<tr>
<td>Female, 21</td>
<td>Syncope</td>
<td>435</td>
<td>SCN5A exon 17</td>
<td>Q1033R, of unknown clinical significance, one previous report</td>
</tr>
<tr>
<td>Female, 39</td>
<td>Asymptomatic</td>
<td>467</td>
<td>SCN5A exon 28</td>
<td>P2005A, pathogenic</td>
</tr>
<tr>
<td>Male, 62</td>
<td>Asymptomatic</td>
<td>481</td>
<td>KCNH2 exon 13</td>
<td>R1047L, pathogenic</td>
</tr>
</tbody>
</table>
Discussion

Our study population consisted of 1,080 subjects with hearing loss, including 441 children younger than 14. Up to date, there is no data in the literature on QTc interval analysis within similar clinical context (hearing loss) and on such a large population. The largest study ever has been conducted in California. It has researched 707 children younger than 6 years old [6]. There is a published study of ECG changes in 162 Polish children aged between 3 and 15 years with a hearing loss. In that cohort, QTc prolongation above the reference value was found in 16 patients (9.9% of the group), while high or intermediate probability of LQTS according to Schwartz’s criteria was identified in 27 (16.6%) children [7]. Furthermore, there has been a study published on 132 children with a hearing loss, among who 5 (3.8%) patients were diagnosed with JL-N syndrome [8]. On the other hand, in 350 Turkish children with congenital sensorineural hearing loss the prevalence of the JL-N syndrome was reported at the 0.7% level [10].

We have not detected a single case of JL-N syndrome among 1,080 studied subjects who were affected by various degrees of hearing loss. It seems to be related to low incidence of this disease in the Central European population. Similarly, the JL-N syndrome has not been detected in earlier mentioned study conducted in California [6]. Fraser et al. [11] estimated that the incidence of this syndrome in the pediatric population aged 4 to 15 years in England, Wales and Ireland was between 1.6 to 6 in 1,000,000. So far, the highest incidence of JL-N syndrome of at least 1:200,000 has been reported in Norway [12].

As noted, since we have diagnosed 5 patients with LQTS genotyping only 60 patients out of 1,027 patients with hearing loss, one can make an estimation, that in a hearing loss population, LQTS can be observed at least with the incidence of around 1 in 205 patients, which is much more than previously reported by Schwartz et al. [13] — 1 in 2,500–3,000 patients. It should be emphasized that the proposed strategy can be used not only for

---

**Table 4. Polymorphisms.**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Change*</th>
<th>Frequency in control group</th>
<th>Frequency in patients with hearing loss</th>
<th>P</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>KCNQ1 exon 13</td>
<td>S546S</td>
<td>MAF(A) = 0.20</td>
<td>MAF(A) = 0.165</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>KCNQ1 exon 16</td>
<td>Y662Y</td>
<td>MAF(T) = 0.118</td>
<td>MAF(T) = 0.139</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>KCNH2 exon 6</td>
<td>F513F</td>
<td>MAF(A) = 0.368</td>
<td>MAF(A) = 0.34</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>KCNH2 exon 7</td>
<td>I489I</td>
<td>MAF(A) = 0.37</td>
<td>MAF(A) = 0.32</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>KCNH2 exon 8</td>
<td>Y652Y</td>
<td>MAF(A) = 0.40</td>
<td>MAF(A) = 0.609</td>
<td>0.09</td>
<td>Unfavorable allele T</td>
</tr>
<tr>
<td>KCNH2 exon 11</td>
<td>K897T</td>
<td>MAF(G) = 0.129</td>
<td>MAF(G) = 0.196</td>
<td>NS</td>
<td>Occurs in splicing region, regulatory impact</td>
</tr>
<tr>
<td>KCNE1 exon 3</td>
<td>S38G</td>
<td>MAF(A) = 0.331</td>
<td>MAF(A) = 0.29</td>
<td>NS</td>
<td>Serine (allele A) seems to be unfavorable</td>
</tr>
<tr>
<td>SCN5A exon 2</td>
<td>A29A</td>
<td>MAF(A) = 0.22</td>
<td>MAF(A) = 0.39</td>
<td>0.26</td>
<td>Unfavorable allele A</td>
</tr>
<tr>
<td>SCN5A exon 12</td>
<td>H558R</td>
<td>MAF(G) = 0.22</td>
<td>MAF(G) = 0.20</td>
<td>NS</td>
<td>Benign change, regulatory impact</td>
</tr>
<tr>
<td>SCN5A exon 17</td>
<td>E1061E</td>
<td>MAF(T) = 0.08</td>
<td>MAF(T) = 0.07</td>
<td>NS</td>
<td>Rare change</td>
</tr>
<tr>
<td>SCN5A exon 28</td>
<td>D1818D</td>
<td>MAF(A) = 0.49</td>
<td>MAF(A) = 0.50</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>KCNH2 exon 12</td>
<td>A572D</td>
<td>MAF(A) = 0.001</td>
<td>2 cases</td>
<td></td>
<td>Very rare change of unknown significance</td>
</tr>
</tbody>
</table>

*Amino acid abbreviations: S — serine, Y — tyrosine, F — phenylalanine, K — lysine etc.; MAF — minor allelic frequency based on 1000 Genomes, SIFT and PolyPhen
the screening for the JL-N syndrome, but also, for the effective diagnosis of the LQTS.

The incidence of prolonged QTc in populations with a hearing loss was previously estimated at the level of approximately 4% [14, 15]. On the other hand, 2.5% of general neonatal population in Italy has been found to have QTc longer than 440 ms. In this study, the incidence of LQTS was reported at the level of 1:2,000–2,500 [13]. In our study, we have found higher incidence of QT prolongation in patients with hearing loss than previously reported in the general population, and this was particularly noticeable in children. This requires further confirmation in research. Identification of the genetic background of this phenomenon and assessment of the associated risk of dangerous arrhythmias are needed as well. Our results are compatible with those reported by Rokicki et al. [7] and many other authors: Chinagudi et al. [14] (2 of 50 [4%] children with congenital deafness had QTc longer than 450 ms), Niaz et al. [15] (4 of 104 [3.8%] of deaf children in Pakistan had QT longer than 440 ms), Srivastava et al. [16] (deaf girls compared to healthy girls, had significantly longer QTc at rest and after exercise), El Habbal and Mahoney [17] (congenital sensorineural hearing loss was associated with prolonged QT interval in 52 children aged 8.35 years on average; mean QTc 417 ms ranging from 384 ms to 490 ms and Ilhan et al. [18] (QTc was significantly longer in 132 children with congenital hearing loss group vs. the control group; QTc measured 414 ± 42 ms on average, ranging between 319 ms and 572 ms, 5 patients had JL-N syndrome). It cannot be excluded that our method of measuring the QT interval is more accurate than manual measurement. If so, it may be required to modify reference values of the QTc intervals in the pediatric population. However, it should be emphasized that in our study, even in patients with abnormal QTc, the mean QTc interval was only slightly prolonged — still less than 490 ms. Also, no arrhythmia or syncope were observed in any of studied patients and only 3 asymptomatic individuals had pathogenic mutations. Furthermore, despite including 3 so-called large LQTS genes (KCNQ1, KCNH2, SCN5A) responsible for approximately 75% of all LQTS cases and the KCNE1 gene (a so-called small LQTS gene) [19], we identified only 3 mutations in 6 patients that are known to be responsible for the occurrence of LQTS. Additionally, only 3 (5%) patients with mutations had a significant increase in QTc on ECG screening. LQTS types 1 and 2 were found in 2 patients who had been unsuccessfully treated for incorrectly diagnosed epilepsy. As a result of genotyping performed during our study we made the diagnosis of LQTS and started appropriate treatment with good result. This emphasizes the need to differentiate epilepsy with LQTS. The role of the ECG, as a necessary investigation performed in any patient with syncope, along with genetic testing, which has a high diagnostic and prognostic value in LQTS, were both underlined [20, 21]. Our study has once again proven that genetic testing in suspected LQTS should be used routinely in clinical practice [20]. Recently, the role of single nucleotide polymorphisms in KCNH2 and SCN5A genes has been reported as important factor associated with some cardiac diseases. The knowledge about single nucleotide polymorphisms (SNPs) in these genes and their associations with LQTS is limited and controversial, though some studies have revealed longer QT intervals in people with the K897T polymorphism in the KCNH2 gene [22, 23], H558R polymorphism in the SCN5A gene was reported as possibly being able to modify expression of an arrhythmia causing mutations [24, 25]. We don’t know if SNPs in genes which encode sodium and potassium channels in cardiomyocytes may also be associated in various hearing loss processes. In our study, the prevalence of particular SNPs was as in general population. Based on the findings of our study and on other reports we suspect the following alleles to be associated with prolonged QTc in this population: K897T allele of the KCNH2 gene, H558R allele of the SCN5A gene, and A29A allele of the SCN5A gene, or any combination of these alleles, or a combination of these alleles with other genes. Further studies are necessary to prove this hypothesis or to explain the role these alleles play in mechanisms of hearing loss and the QTc prolongation with the inherent risk of arrhythmia. Last but not least, we demonstrated an efficient use of telemedicine to transmit the large amount of ECG studies for a review to a cardiology center. Only selected patients who required further investigations needed to be referred to cardiology clinic. Similar telemedicine approach to ECG screening can be used in other populations.

Limitations of the study
The size of the studied population was too small to encounter such rare syndromes as JN-L is. We noticed that it may be sometimes difficult to measure QT accurately, especially when T wave is flattened. Additionally, in children RR intervals vary significantly from beat to beat and this raises the issue of under- or overestimation of QTc.
Relatively high incidence of QTc prolongation may be due to the method of measurement we used, which is possibly more accurate (enlarged and precise caliper) than manual measurement on ECG printed with the 25 mm/s paper speed. We should point out that none of cited references used this kind of precise technique of measurement. Not all patients from the high-risk group reported for, and some patients refused to participate in further cardiac studies.

Conclusions

Our study confirms that JL-N syndrome is extremely rare in the population of people with hearing loss. QT interval prolongation seems to be more frequent in patients (particularly in children) with hearing impairment than in the general population; to explain this phenomenon further studies are required. In people with long QT interval and coexisting hearing loss, only genetic tests can confirm or rule out LQTS. A careful work up, including genetic testing, should always precede the diagnosis of epilepsy with LQTS. To elucidate the role of particular alleles further studies are necessary. It should be emphasized that ECG screening in a population of patients with hearing loss is important when additionally history of epilepsy, syncope or loss of consciousness is present.

The current technology enables ECG transmission and is very efficient in screening of large populations of patients with no overt heart disease. It allows an expert assessment of the results of the studies and gives an opportunity to single out patients who might have various heart diseases, including these with dangerous arrhythmia.

Acknowledgements

The work was funded by the National Science Center [Grant No. NN 402526739].

Conflict of interest: None declared

References

20. Ackerman MJ, Priori SG, Willems S et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace, 2011; 13: 1077–1109.